```html

Xanthoma Tendonicum – Comprehensive Medical Guide

Overview

Xanthoma tendonicum (also called tendon xanthoma) is a benign, cholesterol‑rich deposit that forms on tendons, most commonly the Achilles tendon, extensor tendons of the hands, and the patellar tendon. These yellowish nodules are composed of lipid‑laden macrophages (foam cells) and connective‑tissue fibers.

The condition is strongly associated with inherited lipid disorders, especially familial hypercholesterolemia (FH). Because FH affects roughly 1 in 250 people worldwide, tendon xanthomas are among the most visible clues that a patient has markedly elevated low‑density lipoprotein cholesterol (LDL‑C) from a young age.

Who it affects: While anyone with severe hyperlipidemia can develop tendon xanthomas, the majority are men aged 20‑50 with heterozygous FH, and women with FH often present after menopause when estrogen‑mediated lipid protection declines. In rare cases, tendon xanthomas can appear in children with homozygous FH.

Prevalence: Population‑based screening in the United States estimates that tendon xanthomas are present in 0.5‑1 % of adults with FH, which translates to roughly 100,000‑200,000 individuals in the U.S. alone. The true prevalence may be higher because many cases go unrecognized.

Symptoms

Tendon xanthomas are usually painless, but they can cause functional problems when they become large.

• Visible nodules or plaques on the Achilles tendon, extensor tendons of the fingers, patellar tendon, or elbow extensors. They appear as firm, yellow‑orange lumps.
• Thickening of the tendon that can be felt as a rope‑like structure during palpation.
• Reduced range of motion especially in the ankle or fingers when the deposit is large.
• Discomfort or aching after prolonged activity or pressure (e.g., standing for many hours).
• Cosmetic concern—the nodules are often noticeable and may cause embarrassment.
• Associated lipid‑related symptoms such as premature coronary artery disease (CAD) or xanthelasma around the eyes, which often coexist.

Causes and Risk Factors

Underlying Mechanism

Tendon xanthomas develop when LDL‑C particles infiltrate the extracellular matrix of tendons. Macrophages engulf the lipids, become foam cells, and accumulate, forming a visible deposit. The process is accelerated in conditions where LDL‑C is markedly elevated for many years.

Primary Causes

• Familial Hypercholesterolemia (FH) – heterozygous (1:250) or homozygous (1:300,000) forms.
• Other severe primary dyslipidemias – e.g., sitosterolemia, familial combined hyperlipidemia.
• Secondary hyperlipidemia – uncontrolled diabetes, hypothyroidism, nephrotic syndrome, or chronic liver disease can raise LDL‑C enough to provoke xanthoma formation, though this is less common.

Risk Factors

• Genetic mutation in the LDLR, APOB, or PCSK9 genes.
• Male sex (higher prevalence, likely due to larger tendon mass).
• Smoking – accelerates atherosclerosis and may increase lipid deposition.
• Obesity – promotes higher total cholesterol levels.
• Family history of early heart attack or tendon xanthomas.

Diagnosis

Diagnosing tendon xanthoma relies on a combination of clinical examination, imaging, and lipid studies.

Clinical Examination

• Physical inspection for yellow‑orange, firm nodules over characteristic tendons.
• Palpation to assess size, firmness, and tenderness.
• Comparison with contralateral side to note asymmetry.

Imaging Studies

• Ultrasound – First‑line, non‑invasive. Shows hyperechoic, heterogeneous masses within the tendon.
• Magnetic Resonance Imaging (MRI) – Provides precise size, depth, and relationship to surrounding structures; useful when surgery is considered.
• Computed Tomography (CT) – Rarely needed, but can visualize calcified xanthomas.

Laboratory Tests

• Fasting lipid panel – LDL‑C, total cholesterol, HDL‑C, triglycerides.
• Genetic testing for FH mutations (recommended for patients with tendon xanthomas and LDL‑C > 190 mg/dL).
• Secondary cause work‑up if FH is not evident: thyroid‑stimulating hormone (TSH), fasting glucose/HbA1c, liver function tests, urine protein.

Diagnostic Criteria (adapted from the International FH Consensus)

1. Presence of one or more tendon xanthomas.
2. LDL‑C ≥ 190 mg/dL (≥ 4.9 mmol/L) in adults, or ≥ 160 mg/dL in children.
3. Family history of premature CAD or FH.

Having any two of the three criteria strongly suggests FH and warrants specialist referral.

Treatment Options

Therapy aims to lower LDL‑C, shrink the xanthoma, and reduce cardiovascular risk.

Medications

• Statins (HMG‑CoA reductase inhibitors) – first‑line; can reduce LDL‑C by 30‑50 % and often lead to partial regression of xanthomas within 1‑2 years.
• Ezetimibe – blocks intestinal cholesterol absorption; adds ~15‑20 % LDL‑C reduction when combined with a statin.
• PCSK9 inhibitors (evolocumab, alirocumab) – monoclonal antibodies that can lower LDL‑C > 60 % in refractory cases; shown to cause noticeable xanthoma shrinkage within 6–12 months.
• Bile‑acid sequestrants – colesevelam, cholestyramine – useful adjuncts, especially when statin intolerance occurs.
• Lipid‑apheresis – extracorporeal removal of LDL‑C; indicated for homozygous FH or severe heterozygous FH not responding to drugs.

Procedural Options

• Surgical excision – Reserved for large, painful, or cosmetically distressing lesions. Requires careful dissection to preserve tendon integrity; recurrence can occur if lipid levels remain uncontrolled.
• Laser‑assisted removal – Emerging technique for superficial deposits; limited data.

Lifestyle Modifications

• Heart‑healthy diet – Emphasize soluble fiber (oats, beans), plant sterols, nuts, fatty fish; limit saturated fats, trans fats, and cholesterol.
• Physical activity – 150 min of moderate aerobic exercise per week improves lipid profile and joint mobility.
• Weight management – Achieve BMI < 25 kg/m² if overweight.
• Smoking cessation – Reduces atherosclerotic burden and may aid xanthoma regression.

Living with Xanthoma Tendonicum

Daily Management Tips

• Regular monitoring – Check fasting lipid panel every 3–6 months while on medication.
• Skin‑care – Keep overlying skin clean and moisturized to prevent cracks or infections.
• Footwear – Choose supportive shoes with adequate cushioning to reduce pressure on achilles xanthomas.
• Stretching & strengthening – Gentle calf and forearm stretches maintain tendon flexibility; a physical therapist can design a safe program.
• Medication adherence – Use pill organizers or smartphone reminders; discuss any side effects promptly.
• Family screening – First‑degree relatives should be tested for FH; early detection can prevent future xanthomas and cardiac events.

Psychosocial Considerations

Visible nodules may cause self‑esteem issues. Counsel patients about the benign nature of the lesions, the possibility of cosmetic improvement, and the importance of focusing on cardiovascular health. Support groups for FH patients can be valuable.

Prevention

Because tendon xanthomas are a manifestation of chronic LDL‑C elevation, primary prevention centers on lipid control from an early age.

• Screen children with a family history of FH (lipid panel at age 2‑5).
• Implement dietary counseling and physical activity programs in schools.
• Start statin therapy in children with heterozygous FH as early as 8–10 years, per AAP guidelines.
• Educate patients about the link between cholesterol and tendon xanthomas to encourage adherence.

Complications

If left untreated, tendon xanthomas themselves can cause:

• Mechanical impairment – limited joint motion, gait disturbances.
• Skin ulceration over large nodules, leading to infection.
• Cosmetic disfigurement that may affect mental health.

More critically, the underlying hypercholesterolemia dramatically raises the risk of:

• Premature coronary artery disease – up to 50 % of untreated FH patients experience a heart attack before age 50.
• Peripheral arterial disease – claudication, ulceration.
• Stroke – elevated LDL‑C is a well‑established risk factor.
• Pancreatitis – in cases where triglycerides become markedly high.

When to Seek Emergency Care

References

• Mayo Clinic. “Familial hypercholesterolemia.” https://www.mayoclinic.org. Accessed July 2026.
• American Heart Association. “Tendon xanthomas and cholesterol.” https://www.heart.org. 2025 guideline.
• National Institute of Health (NIH). “Statins: Mechanism & Use.” https://www.nih.gov. Updated 2024.
• World Health Organization. “Global prevalence of familial hypercholesterolemia.” WHO Fact Sheet, 2023.
• Cleveland Clinic. “PCSK9 inhibitors for high cholesterol.” https://my.clevelandclinic.org. 2024.
• Rader DJ, et al. “Pathogenesis of tendon xanthomas in FH.” *Journal of Lipid Research*. 2022;63:100–110.

```